TSVT News and Press, 2seventy bio Inc. From 07/28/23

2023-07-28 09:47:07 ET More on 2seventy bio 2seventy bio: Nothing Properly Explains The Low Valuation 2seventy bio posts Phase 1 results for CAR-T therapy in bone marrow cancer Bristol Myers, 2seventy bio blood cancer drug Abecma gets review in US, EU, Japan for expa...

2023-07-27 08:17:16 ET Bristol-Myers Squibb ( NYSE: BMY ) traded lower pre-market Thursday after announcing lower than expected financials for Q2 2023 and setting its full-year outlook below the consensus, citing competition from cheaper generics. The company’s topline fo...

2023-07-21 11:08:50 ET Summary On July 27, 2023, Bristol-Myers Squibb, one of the leaders in the global cancer and immunology therapeutics market, will release its financial report for the second quarter of 2023. In the first half of 2023, the company delighted investors with nume...

2023-06-21 16:58:52 ET Summary 2seventy bio, Inc. was spun off from bluebird bio, Inc., and has one product in the market making decent revenue. They have a good cash position, a decent if early stage pipeline, and strong collaborations. Thus, their currently low market cap do...

2023-06-14 10:03:06 ET Gainers: Inventiva ( IVA ) +25% . Gossamer Bio ( GOSS ) +21% . Akoya Biosciences ( AKYA ) +19% . InVivo Therapeutics ( NVIV ) +14% . Bone Biologics ( BBLG ) +13% . Losers: IO Biotech ( IOBT ...

2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute Myeloid Leukemia (AML) has been paused by Seattle Children’s, the Company’s partner and the regulatory sponsor of t...

2seventy bio, Inc . (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that members of the management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 6:20pm ET in Dana Poi...

2023-05-19 07:01:26 ET Cell and gene therapy company 2seventy bio, Inc. ( NASDAQ: TSVT ) on Friday announced results from its ongoing Phase 1 trial for CD33-targeting chimeric antigen receptor (CAR) T cell therapy, SC-DARIC33 in patients with bone marrow cancer acute myeloid leukemi...

Results of preliminary correlative analysis from the PLAT-08 study show rapamycin-regulated in vivo expansion and activation of SC-DARIC33 T cells as well as concurrent anti-CD33 activity Enhanced anti-acute myeloid leukemia (AML) potency was obtained with the combination of regulated...

bbT369, a dual-targeted (CD79a/CD20) and CBLB gene edited autologous CAR T for non-Hodgkin lymphoma, showed edit-driven enhanced T cell activity in multiple preclinical models RESET, a novel TCR coupled antigen receptor architecture, displayed markedly increased targeting sensitivity and ...